Amicus Therapeutics Inc (NASDAQ: FOLD) stock suffered a major decline of -12.2% on 11/9/23. The shares closed at $9.98. The stock has been strong relative to the market over the last nine months but has declined -9.2% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, FOLD is expected to be a major Value Builder.
Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Amicus Therapeutics has a very low Appreciation Score of 1 but a neutral Power Rating of 57, leading to the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment